表紙
市場調査レポート

評価項目:自己免疫疾患における臨床試験 - 成功を確実にするため、ますます適用されつつある多角的な1次・2次評価項目

Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success

発行 GBI Research 商品コード 231737
出版日 ページ情報 英文 135 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
評価項目:自己免疫疾患における臨床試験 - 成功を確実にするため、ますます適用されつつある多角的な1次・2次評価項目 Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success
出版日: 2012年02月14日 ページ情報: 英文 135 Pages
概要

当レポートでは、自己免疫疾患の5大疾患 - 多発性硬化症、関節リウマチ、クローン病、潰瘍性大腸炎、乾癬について取り上げ、上市製品のデータと分析、上市製品の効能と安全性の分析、疾患別の分析、第3段階、第2段階および中止された臨床試験の分析、5大疾患の最も有望な分子の分析を提供しており、企業プロファイルを含め、概略以下の構成でお届けいたします。

第1章 目次

第2章 評価項目:自己免疫疾患の臨床試験:概要

  • イントロダクション
  • 評価項目の種類
  • GBI Research のレポートガイダンス

第3章 自己免疫疾患の5大疾患とその製品プロファイリング

  • 評価項目:主な上市製品とその規制認可
    • 多発性硬化症
    • 関節リウマチ
    • クローン病
    • 潰瘍性大腸炎
    • 乾癬

第4章 上市製品・パイプライン製品の評価

  • 多発性硬化症
    • 1次評価項目
    • 2次評価項目
    • 主要上市薬の安全性・効能分析
    • 第3段階臨床試験の分析
    • 最も有望な薬剤のプロファイル
    • 第2段階臨床試験の分析
    • 中止試験の分析
  • 関節リウマチ
    • 1次評価項目
    • 2次評価項目
    • 主要上市薬の安全性・効能分析
    • 第3段階臨床試験の分析
    • 最も有望な薬剤のプロファイル
    • 第2段階臨床試験の分析
    • 中止試験の分析
  • クローン病
    • 1次評価項目
    • 2次評価項目
    • 主要上市薬の安全性・効能分析
    • 第3段階臨床試験の分析
    • 最も有望な薬剤のプロファイル
    • 第2段階臨床試験の分析
    • 中止試験の分析
  • 潰瘍性大腸炎
    • 1次評価項目
    • 2次評価項目
    • 主要上市薬の安全性・効能分析
    • 第3段階臨床試験の分析
    • 最も有望な薬剤のプロファイル
    • 第2段階臨床試験の分析
    • 中止試験の分析
  • 乾癬
    • 1次評価項目
    • 2次評価項目
    • 主要上市薬の安全性・効能分析
    • 第3段階臨床試験の分析
    • 最も有望な薬剤のプロファイル
    • 第2段階臨床試験の分析
    • 中止試験の分析

第5章 企業プロファイル

  • Biogen Idec Inc
    • 企業概要
    • 主な自己免疫疾患薬
  • Amgen Inc
    • 企業概要
    • 主な自己免疫疾患薬
  • Johnson & Johnson
    • 企業概要
    • 主な自己免疫疾患薬
  • Teva Pharmaceutical Industries Limited
    • 企業概要
    • 主な自己免疫疾患薬
  • Shire Plc
    • 企業概要
    • 主な自己免疫疾患薬
  • F. Hoffmann-La Roche Ltd
    • 企業概要
    • 主な自己免疫疾患薬
  • Merck KGaA
    • 企業概要
    • 主な自己免疫疾患薬

第6章 付録

図表

目次

Summary

Autoimmune disorders represent a collective group of disorders which primarily arise due to an overactive immune response of the body against substances and tissues normally present within the body. Most of them cause significant morbidity and disability and are very difficult to diagnose. The cause of autoimmune diseases remains unknown, although genetic factors play a major role in susceptibility. Some of the autoimmune diseases may be triggered by environmental exposure or by an infectious agent. They can attack any tissue or organ of the body and cause a wide range of symptoms and organ injuries, depending on the site of immune attack.

This report details “Endpoints - Clinical Trials in Autoimmune Disorders“, highlighting the five major autoimmune disorders of multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis. The classification of five major autoimmune diseases is based on the number of pipeline molecules present in the Phase III stage of development.

The term endpoint refers to an outcome or measure of a clinical trial. Endpoints can include all kinds of aspects, those related to the effectiveness of treatment and others. However, the endpoint selection must take into account the need to obtain the information of the highest therapeutic interest with the least risk and discomfort for the individual. Also, the endpoints must be aligned with the objectives of the study and represent the most effective way to assess pharmacological response.

Scope

This report details the clinical trial endpoints in autoimmune disorders. The report covers:

  • Data and analysis on the marketed products and analysis of their efficacy and safety details
  • Analysis of the five major autoimmune diseases: Multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis.
  • Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Also analysis of terminated trials is included in this chapter. Only industry-sponsored studies are included in the report.
  • Analysis on most promising molecules of the five major autoimmune diseases with emphasis on their efficacy and safety details.
  • The Company Profiling details the companies that are strong in the market

Reasons to buy

The report will help business development and marketing executives who are strategizing their product launches to:

  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.

Executive Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success” which provides an insight into different endpoints used in clinical trials in autoimmune disorders. The report examines different aspects of clinical trial endpoints in autoimmune disorders, such as analysis of major marketed autoimmune drugs with an emphasis on safety and efficacy details, Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, most promising autoimmune drugs, and terminated trial analysis. The company profiles highlight the autoimmune drugs of different companies.

ACR Response Criteria - An Endpoint Used in Clinical Trials of Most of the Blockbuster Drugs for Rheumatoid Arthritis

Major marketed drugs for RA are Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Rituxan (rituximab), and Celebrex (celecoxib). With a sales figure of more than one billion, all five drugs are considered to be blockbusters. The endpoints used in their clinical trials are American College of Rheumatology (ACR) criteria. ACR response criteria consist of clinical symptoms and signs of inflammation including fatigue, joint pain, morning stiffness, joint tenderness, joint swelling, and Erythrocyte Sedimentation Rate (ESR). This is a used as a major endpoint in most of the clinical trials for RA.

Most Widely Used Secondary Endpoints in the Clinical Trials for Top Five Autoimmune Disorders

From 2000 to 2010, the ACR response criteria was the most commonly used secondary endpoint in clinical trials for RA, followed by clinical remission which is most widely used in clinical trials for ulcerative colitis. Psoriasis Area Disease Severity (PASI) Score, Expanded Disability Status Scale (EDSS) and Crohn's Disease Activity Index (CDAI) are the secondary endpoints which are most widely used in clinical trials for psoriasis, MS and CD respectively.

Safety and Efficacy Issues and Failure to Meet Primary and Secondary Endpoints Led to Discontinuation of Most Drugs

Antova was developed by Biogen Idec for the treatment of MS and many other diseases. Biogen Idec stopped all clinical trials as some patients experienced signs of blood clots. The company announced that it had halted six of its Phase II clinical trials due to safety issues.

Orencia (abatacept, CTLA4-Ig, BMS-188667), a drug for the treatment of UC developed by Bristol-Myers Squibb, was discontinued. The study was terminated due to a lack of efficacy in the first group of subjects in the induction period.

Raptiva (efalizumab) is a drug designed by Genentech and Merck Serono to treat psoriasis. It was approved in 2003 in the US and prescribed for adults with moderate to severe chronic psoriasis. In October 2008, the US Food and Drug Administration (FDA) passed a rule that the drug must carry stricter warnings about the risk of Progressive Multifocal Leukoencephalopathy (PML), a brain disorder caused by reactivation of latent John Cunningham (JC) virus infection due to its action of suppressing the immune system. On March 13, 2009, the FDA approved safety labeling revisions for Raptiva regarding the risks associated with the drug, leading to its withdrawal from the market as of June 8, 2009. The European Medicines Agency (EMEA) recommended the withdrawal of the drug from the European Union (EU) in February 2009 as its associated risks outweighed its efficacy.

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2. Endpoints - Clinical Trials in Autoimmune Disorders - Overview

  • 2.1 Introduction
  • 2.2 Types of Endpoints
    • 2.2.1 Primary Endpoints
    • 2.2.2 Secondary Endpoints
  • 2.3 GBI Research Report Guidance

3. Endpoints - Clinical Trials in Autoimmune Disorders - Top Five Autoimmune Disorders and their Product Profiling

  • 3.1 Endpoints - Major Marketed Drugs of Top Five Autoimmune Disorders and their Regulatory Approval
    • 3.1.1 Multiple Sclerosis
    • 3.1.2 Rheumatoid Arthritis
    • 3.1.3 Crohn's Disease
    • 3.1.4 Ulcerative Colitis
    • 3.1.5 Psoriasis

4. Endpoints - Clinical Trials in Autoimmune Disorders - Marketed and Pipeline Products Assessment

  • 4.1 Multiple Sclerosis
    • 4.1.1 Primary Endpoints Used in Multiple Sclerosis Clinical Trials
    • 4.1.2 Secondary Endpoints Used in Multiple Sclerosis Clinical Trials
    • 4.1.3 Major Marketed Drugs-Safety and Efficacy Analysis
    • 4.1.4 Phase III Clinical Trial Analysis
    • 4.1.5 Most Promising Drug Profiles
    • 4.1.6 Phase II Clinical Trial Analysis
    • 4.1.7 Terminated Trials
  • 4.2 Rheumatoid Arthritis
    • 4.2.1 Primary Endpoints Used in Rheumatoid Arthritis Clinical Trials
    • 4.2.2 Secondary Endpoints Used in Rheumatoid Arthritis Clinical Trials
    • 4.2.3 Major Marketed Drugs - Safety and Efficacy Analysis
    • 4.2.4 Phase III Clinical Trial Analysis
    • 4.2.5 Most Promising Drug Profiles
    • 4.2.6 Phase II Clinical Trial Analysis
    • 4.2.7 Terminated Trials
  • 4.3 Crohn's Disease
    • 4.3.1 Primary Endpoints Used in Crohn's Disease Clinical Trials
    • 4.3.2 Secondary Endpoints Used in Crohn's Disease Clinical Trials
    • 4.3.3 Major Marketed Drugs-Safety and Efficacy Analysis
    • 4.3.4 Phase III Clinical Trial Analysis
    • 4.3.5 Most Promising Drug Profiles
    • 4.3.6 Phase II Clinical Trial Analysis
    • 4.3.7 Terminated Trials Analysis
  • 4.4 Ulcerative Colitis
    • 4.4.1 Primary Endpoints Used in Ulcerative Colitis Clinical Trials
    • 4.4.2 Secondary Endpoints Used in Ulcerative Colitis Clinical Trials
    • 4.4.3 Major Marketed Drugs-Safety and Efficacy Analysis
    • 4.4.4 Phase III Clinical Trial Analysis
    • 4.4.5 Most Promising Drug Profiles
    • 4.4.6 Phase II Clinical Trial Analysis
    • 4.4.7 Terminated Trials Analysis
  • 4.5 Psoriasis
    • 4.5.1 Primary Endpoints Used in Psoriasis Clinical Trials
    • 4.5.2 Secondary Endpoints Used in Psoriasis Clinical Trials
    • 4.5.3 Major Marketed Drugs-Safety and Efficacy Analysis
    • 4.5.4 Phase III Clinical Trial Analysis
    • 4.5.5 Most Promising Drugs' Profiles
    • 4.5.6 Phase II Clinical Trial Analysis
    • 4.5.7 Terminated Trials Analysis

5. Endpoints - Clinical Trials in Autoimmune Disorders - Company Profiling

  • 5.1 Biogen Idec Inc
    • 5.1.1 Company Overview
    • 5.1.2 Major Autoimmune Disease Drugs
  • 5.2 Amgen Inc
    • 5.2.1 Company Overview
    • 5.2.2 Major Autoimmune Disease Drugs
  • 5.3 Johnson & Johnson
    • 5.3.1 Company Overview
    • 5.3.2 Major Autoimmune Disease Drugs
  • 5.4 Teva Pharmaceutical Industries Limited
    • 5.4.1 Company Overview
    • 5.4.2 Major Autoimmune Disease Drugs
  • 5.5 Shire Plc
    • 5.5.1 Company Overview
    • 5.5.2 Major Autoimmune Disease Drugs
  • 5.6 F. Hoffmann-La Roche Ltd
    • 5.6.1 Company Overview
    • 5.6.2 Major Autoimmune Disease Drugs
  • 5.7 Merck KGaA
    • 5.7.1 Company Overview
    • 5.7.2 Major Autoimmune Disease Drugs

6. Endpoints - Clinical Trials in Autoimmune Disorders - Appendix

  • 6.1 Market Definitions
  • 6.2 Abbreviations
  • 6.3 Research Methodology
    • 6.3.1 Clinical Trial Design Overview
    • 6.3.2 Top Five Indications in Autoimmune Disorders and their Product Profiling
    • 6.3.3 Marketed and Pipeline Products Assessment
    • 6.3.4 Company Profiling
  • 6.4 Contact Us
  • 6.5 Disclaimer
  • 6.6 Sources

List of Tables

  • Table 1: Endpoints - Clinical Trials in Autoimmune Disorders, Multiple Sclerosis, Endpoints for Major Marketed Drugs, Global, 1990-2010
  • Table 2: Endpoints - Clinical Trials in Autoimmune Disorders, Rheumatoid Arthritis, Endpoints for Major Marketed Drugs, Global, 1990 - 2010
  • Table 3: Endpoints - Clinical Trials in Autoimmune Disorders, Ulcerative Colitis, Endpoints for Major Marketed Drugs, Global, 1990 - 2010
  • Table 4: Endpoints - Clinical Trials in Autoimmune Disorders, Psoriasis, Endpoints for Major Marketed Drugs, Global,1990- 2010
  • Table 5: Endpoints - Clinical Trials in Autoimmune Disorders, Multiple Sclerosis, Completed Phase III Trial Molecules, Global, 2000-2010
  • Table 6: Endpoints - Clinical Trials in Autoimmune Disorders, Multiple Sclerosis, Ongoing Phase III Trial Molecules, Global, 2000-2010
  • Table 7: Endpoints - Clinical Trials in Autoimmune Disorders, Most Promising Drugs Under Clinical Development, Multiple Sclerosis, 2011
  • Table 8: Endpoints - Clinical Trials in Autoimmune Disorders, Multiple Sclerosis, Completed Phase II Trial Molecules, Global, 2000-2010
  • Table 9: Endpoints - Clinical Trials in Autoimmune Disorders, Multiple Sclerosis, Ongoing Phase II Trial Molecules, Global, 2000-2010
  • Table 10: Endpoints - Clinical Trials in Autoimmune Disorders, List of Discontinued Drugs for Multiple Sclerosis
  • Table 11: Endpoints - Clinical Trials in Autoimmune Disorders, Rheumatoid Arthritis, Completed Phase III Trial Molecules, Global, 2000-2010
  • Table 12: Endpoints - Clinical Trials in Autoimmune Disorders, Rheumatoid Arthritis, Ongoing Phase III Trial Molecules, Global, 2000-2010
  • Table 13: Endpoints - Clinical Trials in Autoimmune Disorders, Most Promising Drugs Under Clinical Development, Rheumatoid Arthritis, 2011
  • Table 14: Endpoints - Clinical Trials in Autoimmune Disorders, Rheumatoid Arthritis, Completed Phase II Trial Molecules, Global, 2000-2010
  • Table 15: Endpoints - Clinical Trials in Autoimmune Disorders, Rheumatoid Arthritis, Ongoing Phase II Trial Molecules, Global, 2000-2010
  • Table 16: Endpoints - Clinical Trials in Autoimmune Disorders, List of Discontinued Drugs for Rheumatoid Arthritis
  • Table 17: Endpoints - Clinical Trials in Autoimmune Disorders, Crohn's Disease, Completed Phase III Trial Molecules, Global, 2000-2010
  • Table 18: Endpoints - Clinical Trials in Autoimmune Disorders, Crohn's Disease, Ongoing Phase III Trial Molecules, Global, 2000-2010
  • Table 19: Endpoints - Clinical Trials in Autoimmune Disorders, Most Promising Drugs Under Clinical Development, Crohn's Disease, 2009
  • Table 20: Endpoints - Clinical Trials in Autoimmune Disorders, Crohn's Disease, Completed Phase II Trial Molecules, Global, 2000-2010
  • Table 21: Endpoints - Clinical Trials in Autoimmune Disorders, Crohn's Disease, Ongoing Phase II Trial Molecules, Global, 2000-2010
  • Table 22: Endpoints - Clinical Trials in Autoimmune Disorders, Ulcerative Colitis, Completed Phase III Trial Molecules, Global, 2000-2010
  • Table 23: Endpoints - Clinical Trials in Autoimmune Disorders, Ulcerative Colitis, Ongoing Phase III Trial Molecules, Global, 2000-2010
  • Table 24: Endpoints - Clinical Trials in Autoimmune Disorders, Most Promising Drugs Under Clinical Development, Ulcerative Colitis, 2009
  • Table 25: Endpoints - Clinical Trials in Autoimmune Disorders, Ulcerative Colitis, Completed Phase II Trial Molecules, Global, 2000-2010
  • Table 26: Endpoints - Clinical Trials in Autoimmune Disorders, Ulcerative Colitis, Ongoing Phase II Trial Molecules, Global, 2000-2010
  • Table 27: Endpoints - Clinical Trials in Autoimmune Disorders, Psoriasis, Completed Phase III Trial Molecules, Global, 2000-2010
  • Table 28: Endpoints - Clinical Trials in Autoimmune Disorders, Psoriasis, Ongoing Phase III Trial Molecules, Global, 2000-2010
  • Table 29: Endpoints - Clinical Trials in Autoimmune Disorders, Most Promising Drugs Under Clinical Development, Psoriasis, 2009
  • Table 30: Endpoints - Clinical Trials in Autoimmune Disorders, Psoriasis, Completed Phase II Trial Molecules, Global, 2000-2010
  • Table 31: Endpoints - Clinical Trials in Autoimmune Disorders, Psoriasis, Ongoing Phase II Trial Molecules, Global, 2000-2010
  • Table 32: Endpoints - Clinical Trials in Autoimmune Disorders, List of Discontinued Drugs for Psoriasis
  • Table 33: Endpoints - Clinical Trials in Autoimmune Disorders, Biogen Idec Inc, Major Autoimmune Drugs, 2010
  • Table 34: Endpoints - Clinical Trials in Autoimmune Disorders, Amgen Inc, Major Autoimmune Drugs, 2010
  • Table 35: Endpoints - Clinical Trials in Autoimmune Disorders, Johnson & Johnson, Major Autoimmune Drugs, 2010
  • Table 36: Endpoints - Clinical Trials in Autoimmune Disorders, Teva Pharmaceutical Industries Limited, Major Autoimmune Drugs, 2010
  • Table 37: Endpoints - Clinical Trials in Autoimmune Disorders, Shire Plc, Major Autoimmune Drugs, 2010
  • Table 38: Endpoints - Clinical Trials in Autoimmune Disorders, F. Hoffmann-La Roche Ltd, Major Autoimmune Drugs, 2010
  • Table 39: Endpoints - Clinical Trials in Autoimmune Disorders, Merck KGaA, Major Autoimmune Drugs, 2010

List of Figures

  • Figure 1: Endpoints - Clinical Trials in Autoimmune Disorders, Number of Pipeline Products in Phase III of Development, 2011
  • Figure 2: Endpoints - Clinical Trials in Autoimmune Disorders, Multiple Sclerosis, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 3: Endpoints - Clinical Trials in Autoimmune Disorders, Multiple Sclerosis, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 4: Endpoints - Clinical Trials in Autoimmune Disorders, Multiple Sclerosis, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 5: Endpoints - Clinical Trials in Autoimmune Disorders, Multiple Sclerosis, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 6: Endpoints - Clinical Trials in Autoimmune Disorders, Multiple Sclerosis, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 7: Endpoints - Clinical Trials in Autoimmune Disorders, Multiple Sclerosis, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 8: Endpoints - Clinical Trials in Autoimmune Disorders, Multiple Sclerosis, Ongoing Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 9: Endpoints - Clinical Trials in Autoimmune Disorders, Multiple Sclerosis, Ongoing Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 10: Endpoints - Clinical Trials in Autoimmune Disorders, Rheumatoid Arthritis, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 11: Endpoints - Clinical Trials in Autoimmune Disorders, Rheumatoid Arthritis, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 12: Endpoints - Clinical Trials in Autoimmune Disorders, Rheumatoid Arthritis, Completed Phase III Clinical Trials Classified Based on Multiple Endpoints, Global, 2000-2010
  • Figure 13: Endpoints - Clinical Trials in Autoimmune Disorders, Rheumatoid Arthritis, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 14: Endpoints - Clinical Trials in Autoimmune Disorders, Rheumatoid Arthritis, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 15: Endpoints - Clinical Trials in Autoimmune Disorders, Rheumatoid Arthritis, Ongoing Phase III Clinical Trials Classified Based on Multiple Endpoints, Global, 2000-2010
  • Figure 16: Endpoints - Clinical Trials in Autoimmune Disorders, Rheumatoid Arthritis, Ongoing Phase III Clinical Trials Classified Based on Multiple Endpoints, Global, 2000-2010
  • Figure 17: Endpoints - Clinical Trials in Autoimmune Disorders, Rheumatoid Arthritis, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 18: Endpoints - Clinical Trials in Autoimmune Disorders, Rheumatoid Arthritis, Completed Phase II Clinical Trials Classified Based on Multiple Endpoints, Global, 2000-2010
  • Figure 19: Endpoints - Clinical Trials in Autoimmune Disorders, Rheumatoid Arthritis, Ongoing Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 20: Endpoints - Clinical Trials in Autoimmune Disorders, Rheumatoid Arthritis, Ongoing Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 21: Endpoints - Clinical Trials in Autoimmune Disorders, Rheumatoid Arthritis, Ongoing Phase II Clinical Trials Classified Based on Multiple Endpoints, Global, 2000-2010
  • Figure 22: Endpoints - Clinical Trials in Autoimmune Disorders, Crohn's Disease, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 23: Clinical Trials in Autoimmune Disorders, Crohn's Disease, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 24: Endpoints - Clinical Trials in Autoimmune Disorders, Crohn's Disease, Completed Phase III Clinical Trials Classified Based on Multiple Endpoints, Global, 2000-2010
  • Figure 25: Endpoints - Clinical Trials in Autoimmune Disorders, Crohn's Disease, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 26: Endpoints - Clinical Trials in Autoimmune Disorders, Crohn's Disease, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 27: Endpoints - Clinical Trials in Autoimmune Disorders, Crohn's Disease, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 28: Endpoints - Clinical Trials in Autoimmune Disorders, Crohn's Disease, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 29: Endpoints - Clinical Trials in Autoimmune Disorders, Crohn's Disease, Ongoing Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 30: Endpoints - Clinical Trials in Autoimmune Disorders, Crohn's Disease, Ongoing Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 31: Endpoints - Clinical Trials in Autoimmune Disorders, Ulcerative Colitis, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 32: Endpoints - Clinical Trials in Autoimmune Disorders, Ulcerative Colitis, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 33: Endpoints - Clinical Trials in Autoimmune Disorders, Ulcerative Colitis, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 34: Endpoints - Clinical Trials in Autoimmune Disorders, Ulcerative Colitis, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 35: Endpoints - Clinical Trials in Autoimmune Disorders, Ulcerative Colitis, Ongoing Phase III Clinical Trials Classified Based on Multiple Endpoints, Global, 2000-2010
  • Figure 36: Endpoints - Clinical Trials in Autoimmune Disorders, Ulcerative Colitis, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 37: Endpoints - Clinical Trials in Autoimmune Disorders, Ulcerative Colitis, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 38: Endpoints - Clinical Trials in Autoimmune Disorders, Ulcerative Colitis, Ongoing Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 39: Endpoints - Clinical Trials in Autoimmune Disorders, Ulcerative Colitis, Ongoing Phase II Clinical Trials Classified Based on Multiple Endpoints, Global, 2000-2010
  • Figure 40: Endpoints - Clinical Trials in Autoimmune Disorders, Psoriasis, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 41: Endpoints - Clinical Trials in Autoimmune Disorders, Psoriasis, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 42: Endpoints - Clinical Trials in Autoimmune Disorders, Psoriasis, Ongoing, Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 43: Endpoints - Clinical Trials in Autoimmune Disorders, Psoriasis, Ongoing, Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 44: Endpoints - Clinical Trials in Autoimmune Disorders, Psoriasis, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 45: Endpoints - Clinical Trials in Autoimmune Disorders, Psoriasis, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 46: Endpoints - Clinical Trials in Autoimmune Disorders, Psoriasis, Ongoing Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 47: Endpoints - Clinical Trials in Autoimmune Disorders, Psoriasis, Ongoing Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Back to Top